Search clinical trials for: first time in human study

Total 467529 results

ViiV Healthcare
GlaxoSmithKline

Not yet recruiting

First Time in Human Study of Long Acting VH4524184 Formulations

HIV Infections

United States
Eli Lilly and Company

Recruiting

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Elevated Lp(a) | Atherosclerotic Cardiovascular Disease (ASCVD)

United States, Australia, Spain, Canada, Argentina, China, Italy, France, Japan, Taiwan, Korea, Republic of, Denmark, Germany, Hungary, Israel, Austria, Belgium, Netherlands, Brazil, Mexico, Romania, United Kingdom, Greece, Czechia, Poland and more
GlaxoSmithKline

Not yet recruiting

A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants

Systemic Lupus Erythematosus

United Kingdom
GlaxoSmithKline
Medicines for Malaria Venture

Recruiting

A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants

Malaria, Falciparum

United Kingdom
Onward Therapeutics

Recruiting

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

Solid Tumor | Hematological Malignancy

France
GlaxoSmithKline

Recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

Hematologic Diseases | Anaemia, Sickle Cell

United States
ViiV Healthcare

Recruiting

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

HIV Infections

United States
GlaxoSmithKline

Recruiting

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Hepatitis B

United Kingdom
GlaxoSmithKline

Recruiting

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Neoplasms

United States, Australia, Spain, Canada, France, Korea, Republic of, United Kingdom, Japan, China
GlaxoSmithKline
23andMe, Inc.; iTeos Therapeutics

Recruiting

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Neoplasms

United States, Canada, Korea, Republic of, Japan
AstraZeneca

Active, not recruiting

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Melanoma | Cervical Cancer | Small Cell Lung Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumours | Non-Small-Cell Lung Cancer | Gastroesophageal Cancer | Clear Cell Renal Cell Cancer | Squamous Cell Cancer of Head and Neck

United States, Spain, Canada, France
Hoffmann-La Roche
Genentech, Inc.; Breast International Group

Active, not recruiting

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

Breast Cancer

United States, Belgium, Canada, Australia, Austria, Bulgaria, China, Croatia, Denmark, France, Germany, Guatemala, Hungary, Ireland, Italy, Korea, Republic of, Panama, Slovenia, Spain, Taiwan, United Kingdom, Colombia, Czechia, El Salvador and more
GlaxoSmithKline

Active, not recruiting

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Neoplasms

Spain, Netherlands, United States, Japan, France, Australia, Korea, Republic of, Canada
CSL Behring

Completed

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

Acute Coronary Syndrome

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Latvi... and more
GlaxoSmithKline

Terminated

A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants

Heart Failure

United Kingdom
GlaxoSmithKline

Active, not recruiting

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

Herpes Simplex

Germany, United States, Belgium, Canada, Spain, United Kingdom, Estonia, Australia
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults

Virus Diseases

United States
GlaxoSmithKline

Active, not recruiting

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Cytomegalovirus Infections

United States
SciNeuro

Completed

A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease

Neurodegenerative Diseases | Alzheimer's Disease

Australia
GlaxoSmithKline

Withdrawn

A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants

Colitis, Ulcerative

United Kingdom
Hoffmann-La Roche
Breast International Group; Frontier Science & Technology Research Foundation... and other collaborators

Completed

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030)

Triple Negative Breast Cancer

Russian Federation, United States, Israel, Italy, Spain, France, Korea, Republic of, United Kingdom, Denmark, Taiwan, Hungary, Argentina, Australia, Austria, Belgium, Brazil, China, Germany, Hong Kong, Japan, Mexico, Romania, Switze... and more
ViiV Healthcare

Completed

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

HIV Infections

United States
ViiV Healthcare

Completed

GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers

HIV Infections

United States
ViiV Healthcare

Completed

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

HIV Infections

United States
GlaxoSmithKline

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole

Celiac Disease | Coeliac Disease

United Kingdom
Gan and Lee Pharmaceuticals, USA

Completed

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

Diabetes Mellitus, Type 2

United States
NorthSea Therapeutics B.V.

Completed

A Phase 1, First Time in Humans Study of NST-1024

Hypertriglyceridemia

United Kingdom
Scancell Ltd

Active, not recruiting

A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection

COVID-19

South Africa
GlaxoSmithKline

Terminated

First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)

Neoplasms

United States, Spain, Canada, Australia
BerGenBio ASA

Completed

A First-time-in-human Study of BGB149

Healthy Volunteers

United Kingdom
Ivashkin Vladimir Trofimovich
Abbott

Completed

Experimental Study to Determine the Effects of Human Refluxate on Macrophage Phenotype and Its Correlation With GERD

Gastroesophageal Reflux Disease (GERD)

Russian Federation
AstraZeneca
Parexel

Completed

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

Metabolic Disorders | Non-alcoholic Steatohepatitis

United States
ViiV Healthcare

Terminated

Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

HIV Infections

United States
Theravance Biopharma
GlaxoSmithKline

Completed

Study of GSK961081 in Healthy Volunteer Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Terminated

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Herpes Simplex

United States
ViiV Healthcare
GlaxoSmithKline

Completed

GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers

HIV Infections | Infection, Human Immunodeficiency Virus

United Kingdom
Julio Ramirez
University of Louisville

Terminated

Patients Response to Early Switch To Oral:Osteomyelitis Study (PRESTO:Osteo)

Osteomyelitis

United States
GlaxoSmithKline
Parexel

Completed

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis

Psoriasis

Germany, United Kingdom
Galecto Biotech AB

Completed

A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects

Safety and Tolerability

United Kingdom
GlaxoSmithKline

Completed

First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma

Asthma

United Kingdom, Germany
Imperial College London
Wellcome Trust; Imperial College Healthcare NHS Trust

Completed

A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects

Obesity

United Kingdom
GlaxoSmithKline

Terminated

First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699

Arthritis, Rheumatoid

United Kingdom
GlaxoSmithKline

Terminated

GSK2983559 First Time in Human Study

Inflammatory Bowel Diseases

United Kingdom
GlaxoSmithKline
Parexel

Terminated

First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

Neoplasms, Pancreatic

United States
GlaxoSmithKline

Completed

First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect

Muscular Dystrophies

United States
Eli Lilly and Company
Insulet Corporation

Completed

An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus (VIVID)

Type 2 Diabetes Mellitus

United States, Puerto Rico
Servier (Tianjin) Pharmaceutical Co. LTD.

Completed

Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes (CODMS)

Type 2 Diabetes

China
China Academy of Chinese Medical Sciences
Renmin Hospital of Wuhan University; Children's Hospital of Soochow University and other collaborators

Unknown

Clinical Study of Reduning Injection for the Treatment of Influenza in Children

Influenza in Children
GlaxoSmithKline

Completed

A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers

Irritable Bowel Syndrome

Australia
GlaxoSmithKline

Completed

First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects

Hepatitis B

United Kingdom

3

Subscribe